MarketCap
Facebook
X
Telegram
Spero Therapeutics P/S Ratio | SPRO
Annual P/S Ratio Spero Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.99 | 2.67 | 0.843 | 0.99 | 20.1 | 35.3 | 9.69 | 38.4 | 16.2 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 38.4 | 0.843 | 14 |
P/S Ratio of other stocks in the Biotechnology industry
| Issuer | P/S Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aptevo Therapeutics
APVO
|
3.11 | $ 1.8 | 2.27 % | $ 568 K |  USA |
 |
Aquestive Therapeutics
AQST
|
10.5 | $ 4.57 | 0.44 % | $ 489 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
2.65 | $ 14.66 | 12.51 % | $ 401 M |  Israel |
 |
Ardelyx
ARDX
|
3.98 | $ 3.39 | 1.5 % | $ 817 M | USA |
 |
argenx SE
ARGX
|
311 | $ 912.87 | 1.28 % | $ 56 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
110 | $ 3.66 | 3.98 % | $ 133 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
9.15 | $ 25.15 | 0.04 % | $ 3.2 B | USA |
 |
Arvinas
ARVN
|
3.31 | $ 7.46 | 0.67 % | $ 529 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
7.54 | $ 62.35 | 0.12 % | $ 8.34 B | USA |
 |
Assembly Biosciences
ASMB
|
4.27 | $ 22.74 | 0.89 % | $ 255 M | USA |
 |
Ascendis Pharma A/S
ASND
|
18.2 | $ 228.03 | 0.07 % | $ 13.8 B |  Danmark |
 |
Actinium Pharmaceuticals
ATNM
|
343 | $ 1.2 | 2.56 % | $ 37.4 M | USA |
 |
Atossa Therapeutics
ATOS
|
4.2 K | $ 2.45 | 4.7 % | $ 21.1 M | USA |
 |
Atara Biotherapeutics
ATRA
|
0.61 | $ 9.4 | 1.16 % | $ 118 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
24.1 | $ 15.72 | 0.49 % | $ 2.11 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
4.27 | $ 1.83 | 2.81 % | $ 487 M |  Britain |
 |
Atea Pharmaceuticals
AVIR
|
2.11 | $ 5.13 | 0.18 % | $ 418 M | USA |
 |
Axon Enterprise
AXON
|
11 | $ 411.81 | 0.69 % | $ 32.2 B | USA |
 |
Axsome Therapeutics
AXSM
|
13.6 | $ 177.08 | 0.73 % | $ 8.81 B | USA |
 |
Aytu BioScience
AYTU
|
0.477 | $ 2.04 | 1.45 % | $ 25.1 M | USA |
 |
BridgeBio Pharma
BBIO
|
26.1 | $ 66.14 | 0.51 % | $ 12.7 B | USA |
 |
BioCardia
BCDA
|
57.2 | $ 1.09 | 4.81 % | $ 7.27 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
2.57 | $ 8.1 | 0.31 % | $ 1.7 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
4.84 | $ 4.01 | 18.64 % | $ 278 M | Britain |
 |
Black Diamond Therapeutics
BDTX
|
1.78 | $ 1.94 | 2.65 % | $ 110 M | USA |
 |
Beam Therapeutics
BEAM
|
22.9 | $ 25.67 | 4.78 % | $ 2.54 B | USA |
 |
Biogen
BIIB
|
2.97 | $ 223.59 | 1.69 % | $ 32.8 B | USA |
 |
BioLineRx Ltd.
BLRX
|
4.78 K | $ 2.32 | 0.43 % | $ 5.72 B | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
3.63 | $ 57.54 | 0.63 % | $ 11 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
2.54 | $ 58.81 | 0.53 % | $ 120 B | USA |
 |
Benitec Biopharma
BNTC
|
54.5 | $ 9.23 | 2.78 % | $ 430 M | USA |
 |
BioNTech SE
BNTX
|
35.7 | $ 97.64 | 0.76 % | $ 23.6 B |  Germany |
 |
Burford Capital Limited
BUR
|
6.73 | $ 3.55 | 0.51 % | $ 778 M | Britain |
 |
BeyondSpring
BYSI
|
28.1 | $ 0.79 | 2.12 % | $ 32.5 M | USA |
 |
Cabaletta Bio
CABA
|
50.3 M | $ 2.08 | 4.0 % | $ 209 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
11.9 | $ 2.14 | 0.45 % | $ 3.52 M | Israel |
 |
Capricor Therapeutics
CAPR
|
49.3 | $ 7.78 | 0.11 % | $ 362 M | USA |
 |
Catalyst Biosciences
CBIO
|
8.57 | $ 13.94 | 0.42 % | $ 1.25 B | USA |
 |
C4 Therapeutics
CCCC
|
6.5 | $ 2.99 | 1.36 % | $ 248 M | USA |
 |
Codexis
CDXS
|
1.57 | $ 1.39 | 2.21 % | $ 121 M | USA |
 |
Cerus Corporation
CERS
|
2.12 | $ 2.34 | 2.63 % | $ 446 M | USA |
 |
Certara
CERT
|
2.57 | $ 10.07 | 7.59 % | $ 1.62 B | USA |
 |
Cullinan Management
CGEM
|
35.1 | $ 16.04 | 3.42 % | $ 966 M | USA |
 |
Compugen Ltd.
CGEN
|
2.7 | $ 2.31 | 0.43 % | $ 216 M | Israel |
 |
Coherus BioSciences
CHRS
|
5.36 | $ 1.12 | 0.86 % | $ 131 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.32 K | $ 32.59 | 2.97 % | $ 2.16 B | USA |